The effect of octreotide on fasting and postprandial splanchnic hemodynamics in cirrhosis.

[1]  P. Hůlek,et al.  Management of Acute Variceal Bleeding , 2003, Digestive Diseases.

[2]  G. D’Amico,et al.  Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. , 2003, Gastroenterology.

[3]  R. Groszmann,et al.  Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. , 2001, Gastroenterology.

[4]  K. Kerlikowske,et al.  Octreotide for acute esophageal variceal bleeding: a meta-analysis. , 2001, Gastroenterology.

[5]  J. Henriksen,et al.  Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. , 1997, Journal of hepatology.

[6]  A. Toyonaga,et al.  Postprandial splanchnic hemodynamic response in patients with cirrhosis of the liver: evaluation with "triple-vessel" duplex US. , 1996, Radiology.

[7]  R. Groszmann,et al.  Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portal-hypertensive rats. , 1996, Gastroenterology.

[8]  L. Roberts,et al.  Pathophysiology and treatment of variceal hemorrhage. , 1996, Mayo Clinic proceedings.

[9]  G. D’Amico,et al.  The treatment of portal hypertension: A meta‐analytic review , 1995, Hepatology.

[10]  R. Groszmann,et al.  Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study , 1995, Hepatology.

[11]  S. D. Lee,et al.  Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. , 1994, Journal of hepatology.

[12]  F. Chan,et al.  Octreotide infusion or emergency sclerotherapy for variceal haemorrhage , 1993, The Lancet.

[13]  N. Mcintyre,et al.  Octreotide inhibits the meal‐induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double‐blind, placebo‐controlled study , 1992, Hepatology.

[14]  S. D. Lee,et al.  Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. , 1992, Gastroenterology.

[15]  M. Keogan,et al.  Postprandial changes in portal haemodynamics in patients with cirrhosis. , 1992, Gut.

[16]  R. Casamitjana,et al.  Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. , 1991, Gastroenterology.

[17]  R. Groszmann,et al.  Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: An operator‐blind echo‐Doppler study , 1991, Hepatology.

[18]  O. Garden,et al.  The effect of a long‐acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis , 1988, Alimentary pharmacology & therapeutics.

[19]  R. Casamitjana,et al.  Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. , 1988, The American journal of physiology.

[20]  J. Wahren,et al.  Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. , 1987, Scandinavian journal of gastroenterology.

[21]  V. Go,et al.  Role of glucagon in splanchnic hyperemia of chronic portal hypertension. , 1986, The American journal of physiology.

[22]  J. Wahern.  The influence of a Long-acting samatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis , 1986 .

[23]  J. Wahren,et al.  The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. , 1986, Scandinavian journal of gastroenterology. Supplement.

[24]  M. Paller,et al.  Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a post-receptor defect in angiotensin action. , 1985, Circulation research.

[25]  A. P. Shepherd,et al.  Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. , 1985, The American journal of physiology.